Several factors should be considered when clinically diagnosing BBS

Look at your patient's complete presentation

Clinical manifestations1-3

  • BBS is a ciliopathy with a highly variable phenotype and clinical features that vary greatly across individuals and evolve over time
  • Some features may present more mildly or slowly depending on gene variant and other factors
Download the brochure below to find out more about how BBS may present in your practice
Download

Genetics3

  • Genetic testing for BBS can provide additional diagnostic information to help inform your diagnosis. For more information, visit UncoveringRareObesity.com
  • Results should be integrated into the overall clinical assessment of the patient and do not equate to a diagnosis on their own. Additionally, variant interpretation may change over time, as the information around the genetics of BBS continue to evolve

Patient history

  • Review patients’ complete medical history. Some clinical manifestations of BBS may have been previously treated and/or not recognized as a symptom of BBS

Family findings1,4

  • Family members have an increased risk of inheriting a pathogenic BBS gene, and siblings are generally diagnosed earlier
  • Once one family member is diagnosed, others should be evaluated for BBS as well
  • Phenotype can vary between siblings
Announcing the ICD-10 code for BBS - Q87.83 - effective as of October 1, 2023

Announcing the ICD-10 code for BBS—Q87.83—effective as of October 1, 2023

BBS has a highly variable phenotype with key identifiable features2

BBS is clinically and genetically diverse, so not all people with BBS will present the same way or with all of these features1,3

← Swipe left or right to view →

BirthFirst years of life(0 to 5 years)Eary childhood(up to 10 years)Adolescence to adulthood(>10 years)
Postaxial polydactyly2,4-7Extra digits (postaxial)Typically surgically removed
Renal anomalies2,4,8Anatomical malformationsProgressive kidney diseasePolyuria/PolydipsiaChronic kidney disease
Hyperphagia and obesity2,9-12Normal birth weightRapid weight gain leading to early-onset, severe obesity, unusual food seekingHyperphagia and severe obesity persistContinued hyperphagia and severe obesity persist, presenting as truncal obesity for adults
Cognitive impairment2,13Developmental delay,
speech delay
Specialized schooling needs, behavioral difficulties Learning difficulties
Visual impairment2,14Progressive vision loss,
night blindness
Legal blindness
Hypogonadism2,13Delayed puberty,
genital anomalies

Diagnosing BBS in your practice

Recognize the various clinical manifestations of BBS to accelerate a diagnosis for your pediatric and adult patients

Uncovering Rare Obesity® can help support a BBS diagnosis

A no-charge,* extensive genetic testing program for MC4R pathway diseases

Lightbulb icon

Extensive panel offers broad insights1

More than 20 genes have been found to be associated with BBS. The gene panel includes 79 genes and 1 chromosome region, reflective of nearly all of the most frequently tested genes associated with obesity.

HCP icon

Tailored support for results interpretation

Access to a geneticist to help interpret results and licensed genetic counselors for your patients are available. Services are provided through third-party partners.

Door icon

Testing conducted by a laboratory partner

DNA testing is conducted by PreventionGenetics, a CLIA-accredited clinical laboratory.

Swab kit icon

Blood and OCD-100 buccal swab
sample collection kits are available.

 

For more information about the genetic testing program, visit UncoveringRareObesity.com

*Rhythm Pharmaceuticals covers the cost of the test and provides sample collection kits. Patients are responsible for office visit, sample collection, or other costs.

See an overview of BBS

CLIA=Clinical Laboratory Improvement Amendments.

References: 1. Forsythe E et al. Front Pediatr. 2018;6:23. doi:10.3389/fped.2018.00023. 2. Forsythe E et al. Eur J Hum Genet. 2013;21(1):8-13. 3. Manara E et al. Ital J Pediatr. 2019;45(1):72. 4. Forsyth R et al. Bardet-Biedl syndrome overview. In: Adam MP et al, eds. GeneReviews®. University of Washington; 2003. Updated July 23, 2020. Accessed August 11, 2023. 5. Khan OA et al. Cureus. 2019;11(2):e4114. 6. Agrawal H et al. Pediatr Rev. 2018;39(5):e21-e23. 7. Vlahovic AM et al. Pediatric and Adolescent Plastic Surgery for the Clinician. Springer;2017:89-105. 8. Putoux A et al. Pediatr Nephrol. 2012;27(1):7-15. 9. Sherafat-Kazemzadeh R et al. Pediatr Obes. 2013;8(5):e64-e67. doi:10.1111/j.2047-6310.2013.00182.x. 10. Pomeroy J et al. Pediatr Obes. 2021;16(2):e12703. 11. Katsanis N et al. Hum Mol Genet. 2001;10(20):2293-2299. 12. Eneli I et al. Appl Clin Genet. 2019;12:87-93. 13. Beales PL et al. J Med Genet. 1999;36(6):437-446. 14. Weihbrecht K et al. Med Res Arch. 2017;5(9):10.18103/mra.v5i9.1526. doi:10.18103/mra.v5i9.1526.
Important Safety Information

Indication

IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome (BBS).

Limitations of Use

IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective:

  • Other types of obesity not related to BBS or other FDA-approved indications for IMCIVREE, including obesity associated with other genetic syndromes and general (polygenic) obesity

Contraindication

Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.

WARNINGS AND PRECAUTIONS

Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

Depression and Suicidal Ideation: Depression and suicidal ideation have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.

Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.

Skin Pigmentation and Darkening of Pre-existing Nevi: Generalized increased skin pigmentation and darkening of pre-existing nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmentary lesions.

Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol-preserved drugs.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection

USE IN SPECIFIC POPULATIONS

Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at 833-789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information for additional Important Safety Information.

Important Safety Information

Indication

IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome (BBS).

Limitations of Use

IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective:

  • Other types of obesity not related to BBS or other FDA-approved indications for IMCIVREE, including obesity associated with other genetic syndromes and general (polygenic) obesity

Contraindication

Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.

WARNINGS AND PRECAUTIONS

Disturbance in Sexual Arousal: Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

Depression and Suicidal Ideation: Depression and suicidal ideation have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.

Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.

Skin Pigmentation and Darkening of Pre-existing Nevi: Generalized increased skin pigmentation and darkening of pre-existing nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmentary lesions.

Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants: IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including “gasping syndrome” can occur in neonates and low birth weight infants treated with benzyl alcohol-preserved drugs.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥20%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection

USE IN SPECIFIC POPULATIONS

Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.

To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at 833-789-6337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information for additional Important Safety Information.